Academic Staff

Assoc. Prof. Dr. Theerut Luangmonkong Assoc. Prof. Dr. Theerut Luangmonkong theerut.lua@mahidol.ac.th theerut.lua@mahidol.ac.th Department of Pharmacology, Faculty of Pharmacy, Mahidol University.

2020

1. Host microbiota dictates the proinflammatory impact of LPS in the murine liver

   Suriguga S, Luangmonkong T, Mutsaers HAM, Groothuis GMM, Olinga P*. Toxicol in vitro 2020; 104920.
   
   

2. Modified culture protocol for testing anti-fibrotic drugs using precision-cut liver slices

   Luangmonkong T, Olinga P*. Pharmaceutical sciences asia 2020; 47(3): 301-309.
   
   

3. Murine precision-cut Intestinal slices as a potential screening tool for antifibrotic drugs.

   Iswandana R, Pham BT, Suriguga S, Luangmonkong T, van Wijk LA, Jansen YJM, Oosterhuis D, Maria Mutsaers HA, Olinga P*. Inflammatory bowel diseases 2020; 26(5): 678-686.
   
   

4. Osteoprotegerin is more than a possible serum marker in liver fibrosis: A study into its function in human and murine liver

   Adhyatmika A, Beljaars L, Putri KSS, Habibie H, Boorsma CE, Reker‐smit C, Luangmonkong T, Guney B, Haak A, Mangnus KA, Post E, Poelstra K, Ravnskjaer K, Olinga P, Melgert BN*. Pharmaceutics 2020; 12(5): 471.
   
   

5. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-β signaling

   Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H*. Frontiers in cardiovascular medicine 2020; 7(34).
   
   

2019

1. A pathophysiological model of non-alcoholic fatty liver disease using precision-cut liver slices

   Prins GH, Luangmonkong T, Oosterhuis D, Mutsaers HAM, Dekker FJ, Olinga P*. Nutrients 2019; 11(3): 507.
   
   

2018

1. In vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β

   Luangmonkong T., Suriguga S., Adhyatmika A., Adlia A., Oosterhuis D., Suthisisang C., de Jong K.P., Mutsaers H.A.M., Olinga P. Toxicology and Applied Pharmacology 2018; 355; 127-237
   
   

2. Targeting Oxidative Stress for the Treatment of Liver Fibrosis

   Luangmonkong T, Suriguga S, Mutsaers HAM, Groothuis GMM, Olinga P, Boersema M. Reviews of Physiology, Biochemistry and Pharmacology 2018; 175: 71-102.
   
   

2017

1. Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

   Luangmonkong T, Suriguga S, Bigaeva E, Boersema M, Oosterhuis D, de Jong KP, Schuppan D, Mutsaers HAM, Olinga P*. British Journal of Pharmacology 2017; 174(18): 3107-3117
   
   

2016

1. Organ- and species-specific biological activity of rosmarinic acid

   Iswandana R, Pham BT, van Haaften WT, Luangmonkong T, Oosterhuis D, Mutsaers HAM, Olinga P*. Toxicology in Vitro 2016; 32: 261-268
   
   

2. Precision-cut human kidney slices as a model to elucidate the process of renal fibrosis

   Stribos EGD, Luangmonkong T, Leliveld AM, De Jong IJ, Van Son WJ, Hillebrands J-L, Seelen MA, Van Goor H, Olinga P*, Mutsaers HAM. Translational Research 2016; 170: 8-16
   
   

2007

1. การตรวจหายีนที่สร้างโปรตีนที่มีฤทธิ์ยับยั้งไรโบโซมในพืชวงศ์ข้าว

   Leelamanit W, Chuethong J, Luangroongsao T, Luangmonkong T. Isan Journal of Pharmaceutical Sciences(IJPS). 2007; 3(2) Jul-Dec: 35-43.
   
   

---

หมายเหตุ: ชื่อที่ใช้ในการทำวิจัยของ Assoc. Prof. Dr. Theerut Luangmonkong ได้แก่ ธีรัตถ์ เหลืองมั่นคง ; Luangmonkong T ;